Bioavailability

Bioavailability refers to the proportion of an administered compound that reaches the systemic circulation in its unchanged, pharmacologically active form. For peptides, bioavailability varies dramatically depending on the route of administration: intravenous delivery achieves 100% bioavailability by definition, subcutaneous injection typically achieves 65-95%, while oral administration of most peptides yields less than 1-2% due to enzymatic degradation in the gastrointestinal tract and first-pass hepatic metabolism. This is why most research peptides are administered via injection rather than orally. ORYN's pre-mixed peptide pen system uses subcutaneous delivery to achieve high bioavailability while offering the convenience and precision of a ready-to-use format. The NovaDose NAD+ system achieves near-100% bioavailability through its advanced subcutaneous microdosing technology.